C-3QRHplacenta-derived cell therapies, allogeneic cellular medicine, advanced biomaterials
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This study will find the maximum tolerated dose (MTD) of CYNK-101 which contains Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-101 will be administered as first-line treatment, following induction therapy consisting of Pembrolizumab, Trastuzumab and a Fluoropyrimidine / Platinum based Chemotherapy regimen. Patients are required to undergo a biopsy for confirmation of HER2 positivity defined as either IHC 3+ or IHC 2+ with a positive fluorescent in-situ hybridization (FISH) or FISH + alone. The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma.
A Phase 1/2a Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001 in Combination with Recombinant Human Interleukin-2 in Adults with Recurrent Resection Eligible IDH1 wild-type Glioblastoma. For phase I portion, the study objectives to assess the safety and feasibility CYNK-001 in combination with rhIL2 of Intravenous (IV) infusion and Intracavitary (IC) administrations following tumor resection and to establish a maximum tolerated dose (MTD) and a Recommended Phase 2a Dose (RP2D) for IV and IC CYNK-001 administration. For Phase IIa, to evaluate efficacy and safety of CYNK-001 administrations in recurrent GBM as measured by Progression Free Survival at 6 months (PFS6M)
This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the systemic cohort (IV) (intravenous). The intratumoral cohort (IT) will not be giving lymphodepletion. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating recurrent glioblastoma multiforme.
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.
This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT). The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating Multiple Myeloma.
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.
This study will find the highest acceptable treatment dose and timing of infusion of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with multiple myeloma. The NK cells will be given at varying days post autologous stem cell transplant. rhIL-2 is administered after treatment to help the NK cells expand in the body. The safety of this treatment will be studied and researchers want to learn if NK cells will help in treating multiple myeloma.
This study will find the highest acceptable treatment dose of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with relapsed and/or refractory acute myeloid leukemia. The NK cells will be given with chemotherapy and Recombinant human interleukin 2 (rhIL-2) to help the NK cells expand in the body. The safety of this treatment will be studied and researchers want to learn if NK cells will help in treating the AML.
This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have diabetic peripheral neuropathy (DPN). The study will enroll approximately 24 subjects. Subjects will be randomized to receive one of 3 treatments: PDA-002 (3 x 10\^6 cells), PDA-002 (30 x 10\^6 cells), or placebo (vehicle control) in a 1:1:1 randomization approach. Investigational product or placebo will be administered monthly (3 administrations total on Study Days 1, 29, and 57).
Study PDA-002-DFU-003 is a Phase 2, multicenter, randomized, double blind, placebo-controlled, dose range finding study in subjects who have diabetic foot ulcer (DFU) with peripheral arterial disease (PAD). The study will enroll approximately 24 subjects. This study will investigate the hemodynamic effects, clinical efficacy, and safety of 3 monthly intramuscular (IM) injections of PDA-002 in subjects who have DFU with PAD.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy and safety of intramuscular administration of human placenta-derived cells (PDA-002) in subjects with diabetic foot ulcers (DFU), including subjects with and without peripheral arterial disease (PAD). Subjects were randomized to receive one of three dose levels of PDA-002 or placebo. Randomization was stratified by PAD status. The study evaluated wound healing and safety outcomes over the follow-up period.
This Phase 1, multicenter, open-label, dose-escalation study evaluated the safety and tolerability of intramuscular administration of PDA-002 (human placenta-derived cells) in subjects with peripheral arterial disease (PAD) and diabetic foot ulcers (DFU).
To assess the safety and efficacy of intravenous (IV) PDA001 infused every two weeks for up to 5 total infusions in subjects with Crohn's disease who are refractory to one or more standard Crohn's disease therapies.
The primary objective of the study is to assess the safety and tolerability of a single dose of PDA001 (given twice) in subjects with Stage II or III Pulmonary Sarcoidosis (PS) who are refractory to one or more of the following treatments for PS: methotrexate,immunosuppressants or cytotoxic agents.
The primary objective of the study is to assess the safety and tolerability of Human Placenta-Derived Cells (PDA001) at 3 different dose levels versus placebo (vehicle control) administered intravenously in subjects following ischemic stroke. The secondary objective of the study is to assess the effect of PDA001 on improvement in clinical function following ischemic stroke.
The primary objective of the study is to assess the safety and efficacy of 2 dose groups (PDA001 versus vehicle control) in subjects with active rheumatoid Arthritis. The secondary objectives of the study are to determine the clinical response at defined visit intervals, determine the time to flare of RA symptoms and to quantify changes in inflammatory markers including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum amyloid A (SAA), and IL-6.
The primary objective of the study is to estimate the treatment effect of PDA001 (evaluating 3 different PDA001 dosings) versus placebo in subjects with moderate-to-severe Crohn's Disease. The secondary objective of the study is to assess the safety and tolerability of PDA001 versus placebo in the above-mentioned patient population.
NexGel’s Celularity Acquisition: Financing, Dilution, and Honest Opinions | Sam McColgan LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn
Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy S … hief Executive Officer of Celularity. “Building on the FDA’s recent decision to grant Fast Track status to CYNK-001, we view the Orphan Drug Designation as yet another milestone on our journey to deliver patients a potentially novel treatment. To date, we have observed the potential of CYNK-001 in multiple preclinical models as well as early evidence of activity in the clinic and believe this approach may shift the paradigm in augmenting the body’s natural immune response to
Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investo
Celularity acquires certain assets from TNK Therapeutics | Experience | Jones Day Skip to content Search     LANGUAGES Deutsch español français português 中文(简体) 中文(繁體) 日本語     SEARCH   Lawyers Practices Insights Locations Values Firm News Inclusion Pro Bono Careers PRINT LANGUAGES Deutsch español français português 中文(简体) 中文(繁體) 日本語 Cases & Deals Home Practices Celularity acquires certain assets from TNK Therapeutics Share Celularity acquires certain assets from TNK Therapeutics August 2017 Client(s) Celularity Inc. Jones Day advised Celularity Inc. in connection with its a
Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expande
Portfolio – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers MENU No items found Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including mesenchymal-like adherent stromal cells (MLASCs), Natural Killer (NK) cells, and engineered T cells including CAR
Life Sciences Luncheon JOIN Become a Member Premier Membership What Members Are Saying > Share a Testimonial Membership Inquiry The Value of Membership > Grow Your Business Build Your Brand Professional Development & Education Government Advocacy Community Outreach & Volunteering New Member Survey Power of Connection About Chamber Team Our Mission Our President Board of Directors Morris Business Cabinet President's Circle Chamber Champions Ambassadors Council Inclusivity Advisory Council Frequently Asked Questions Code of Conduct & COVID Policy Membership Member Benefits Forums & Committ … Events & Programs Nonprofit Excellence Awards Golf Donations 2026 Event Photos Submit an Event Idea CCM Grant-Supported Training Directory Searchable Business Directory Nonprofit Giving Guide Member Spotlights Enhance Your Directory Listing News & Info Electronic Certificate of Origin Business Resources & Info Chamber Magazines News Around the Chamber > Around the Chamber Archive Submit a Press Release MCCC Blog > Contribute to Our Blog Members' Bookshelf > Members … Morris Alumni Council LEAD Morris Alumni Directory Lead Morris FAQs Lead Morris Application LEAD Morris News & Info Share a LEAD Morris Testimonial Women In Business > Women in Business Mastermind Women in Golf Program Entrepreneur Roundtable Thrive Morris > Thrive Morris Community Leaders Thrive Morris Blog Contribute to the Thrive Morris Blog Member Portal Life Sciences Luncheon Items --> Register Register Sponsors Related Links Reminder --> Weather Related Web … Events & Programs Nonprofit Excellence Awards Golf Donations 2026 Event Photos Submit an Event Idea CCM Grant-Supported Training Directory Searchable Business Directory Nonprofit Giving Guide Member Spotlights Enhance Your Directory Listing News & Info Electronic Certificate of Origin Business Resources & Info Chamber Magazines News Around the Chamber > Around the Chamber Archive Submit a Press Release MCCC Blog > Contribute to Our Blog Members' Bookshelf > Members … Morris Alumni Council LEAD Morris Alumni Directory Lead Morris FAQs Lead Morris Application LEAD Morris News & Info Share a LEAD Morris Testimonial Women In Business > Women in Business Mastermind Women in Golf Program Entrepreneur Roundtable Thrive Morris > Thrive Morris Community Leaders Thrive Morris Blog Contribute to the Thrive Morris
OTO Experience Exhibitor List | AAO-HNS Bulletin Clinical Research Professional Development Practice Management Advertise Current Issue Archives Jobs/Events About The Bulletin Topics Current Issue Archives Jobs/Events About The Bulletin Resources Clinical Research Professional Development Practice Management Advertise Published: August 2, 2021 OTO Experience Exhibitor List As of July 20, 2021 * Academy Advantage Premier Partners ** Academy Advantage Partners 3-d Matrix, Inc. 1537 Acclarent, Inc. 1305 Acumed Instruments Corporation & … ment of Obstructive Sleep Apnea (OSA), was held on June 19. Humanitarian Travel Grant: Medical Mission in Guayaquil, Ecuador Jason D. Pou, MD, traveled to Guayaquil, Ecuador, in March 2020 with the Global Smile Foundation (GSF) to provide comprehensive craniofacial care to the underserved local population while educating local healthcare teams for future care. OTO Journal 2020 Impact Factor Is Highest Ever Under the leadership of Editor in Chief John H. Krouse, MD, PhD, MBA, … eved the highest impact factor in its history. BOG 2021 Practitioner Excellence Award The BOG Practitioner Excellence Award recognizes the prototypical clinical otolaryngologist that one wishes to emulate. This year's award recipient is Richard V. Smith, MD. 2021 BOG Model Society Award The Model Society Award recognizes outstanding local/state/regional societies that exhibit effective leadership. This year’s recipient is The Harry Barnes Society. 2021 YPS IMPACT Award The ne … recipient is The Harry Barnes Society. 2021 YPS IMPACT Award The new YPS IMPACT Award recognizes young physicians who are remarkable with regard to the impact they have on education, service to their community, service to their profession, and humanitarian work. This year’s award recipient is Yi-Chun Carol Liu, MD. 2021 YPS Model Mentor Award The YPS Model Mentor Award recognizes an experienced physician whose expert mentorship played a key role in a young physician’s career. … expert mentorship played a key role in a young physician’s career. This year’s award recipient is John H. Krouse, MD, PhD, MBA. 2021 WIO Helen F. Krause, MD Trailblazer Award The Helen F. Krause, MD Trailblazer Award recognizes an individual who has furthered the interests of women in the field of otolaryngology. This year’s award recipient is N
Celularity Announces Closing of Financing Transactions - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases A … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity Announces Closing of Financing Transactions December 23, 2025 | 6 min read Twitter LinkedIn Facebook Email Print FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinion … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter November 19, 2024 | 4 min read Twitter LinkedIn Facebook Email Print FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Op … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing April 20, 2026 | 2 min read Twitter LinkedIn Facebook Email Print FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine comp … s listing rules, the Company has 60 calendar days from receipt of the notice to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company an exception of up to 180 calendar days from the original due date of the Form 10-K to regain compliance. The Company is working diligently to complete and file the Form 10-K as soon as practicable and currently expects to do so in the coming weeks. However, there can be no assurance that the Com … es, the possibility that Nasdaq may not accept the Company’s compliance plan or grant an exception period, the Company’s ability to regain compliance within any period granted by Nasdaq, and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by law. Investor Contact: Carlos Ramirez Senior Vice President, Celularity Inc. Ca … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Men … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities March 13, 2026 | 4 min read Twitter LinkedIn Facebook Email Print Biovance, Biovance 3L, Natalin, Acelagraf … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developmen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies July 18, 2023 | 6 min read Twitter LinkedIn Facebook Email Print Celularity Inc., a biotechnology company developing placental-derived allogeneic cell t … his press release include express or implied statements regarding the potential application of Celularity’s advanced biomaterials, Celularity’s ability to differentiate its products from other human placental derived biomaterial products, and Celularity’s ability to advance its technology platform to develop therapeutic options for unmet patient needs, among others. Many factors could cause actual results to differ materially from those described in these forward-looking stat … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busines … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy March 10, 2026 | 6 min read Twitter LinkedIn Facebook Email Print Transaction expected to generate up to $35 million in upfront and milestone payments Celularity retains exclusive manu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Can … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 5, 2024 | 1 min read Twitter LinkedIn Facebook Email Print FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity Announces Closing of Transaction with NexGel - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity Announces Closing of Transaction with NexGel April 21, 2026 | 3 min read Twitter LinkedIn Facebook Email Print FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced th … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene The … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care October 31, 2025 | 5 min read Twitter LinkedIn Facebook Email Print FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity Appoints Richard J. Berman to its Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press R … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Celularity Appoints Richard J. Berman to its Board of Directors August 28, 2024 | 2 min read Twitter LinkedIn Facebook Email Print Seasoned Public Company Director and Finance Veteran Brings Extensive Track Record of Success in Facilitating the Growth of Shareholder Value FLORHAM PARK, N.J., … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity Appoints Rick Gonzalez as Chief Commercial Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity Appoints Rick Gonzalez as Chief Commercial Officer June 3, 2026 | 6 min read Twitter LinkedIn Facebook Email Print Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank FLORHAM … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release S … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease October 15, 2025 | 8 min read Twitter LinkedIn Facebook Email Print First-in-cl … velopments, Dr. Hariri said, “Celularity is actively assessing opportunities to apply these findings in jurisdictions such as Florida, where PDA-002 qualifies as a stem cell therapy under a new law authorizing use by Florida physicians in wound care, orthopedics, and pain management.” Diabetes afflicts an estimated 2.1 million Floridians according to a January 2025 Florida Diabetes Advisory Council report, which found that the percentage of adult Floridians diagnosed with dia … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer O … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses February 10, 2026 | 4 min read Twitter LinkedIn Facebook Email Print FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine co … eir New Jersey NOLs and R&D tax credits for cash to buyers who purchase and apply the credits to reduce taxable income. The program is operated by the New Jersey Economic Development Authority (NJEDA), which serves as the State’s principal agency for driving economic growth. “The funds Celularity received under this program provide non-dilutive, tax-free capital that strengthens our balance sheet and enhances liquidity as well as supports disciplined capital allocation to … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Th … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company February 25, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Leverages Celularity World-class Manufacturing Capabilities FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing De … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations December 29, 2025 | 6 min read Twitter LinkedIn Facebook Email Print While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Dr. Robert J. Hariri Honored At Unite to Cure, The 4th International Vatican Conference, With The 2018 Pontifical Key Innovation Award - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Dr. Robert J. Hariri Honored At Unite to Cure, The 4th International Vatican Conference, With The 2018 Pontifical Key Innovation Award May 4, 2018 | 2 min read Twitter LinkedIn Facebook Email Print Dr. Robert J. Hariri, Founder and CEO of Celularity, has been awarded with the 2018 Pontifical … and CEO of Celularity, has been awarded with the 2018 Pontifical Key Innovation Award by the Vatican’s Pontifical Council for Culture and the Cura Foundation. WARREN, N.J. and VATICAN CITY, May 4, 2018 /PRNewswire/ -- Dr. Robert J. Hariri, Founder and CEO of Celularity , has been awarded with the 2018 Pontifical Key Innovation Award by the Vatican's Pontifical Council for Culture and the Cura Foundation. The award was announced on Friday, April 27 during Unite to Cure: The Fo … : The Fourth International Vatican Conference in Vatican City . The prestigious award was presented by His Eminence Gianfranco Cardinal Ravasi, President of the Pontifical Council for Culture, and Dr. Robin Smith, President of the Cura Foundation. The award recognizes innovators in medicine who change the course of history and reduce suffering on a global scale by blending visionary thinking with real action. "Dr. Hariri is a visionary who pushes the boundaries of what many c … l Ravasi and Dr. Smith were joined by 15-year-old Quentin Murray to present the award, who at age five was diagnosed with acute lymphoblastic leukemia with less than a 30% chance of survival. Quentin received the first transplant using stem cells from the placenta and umbilical cord from his sister and today, Quentin is 10 years in remission. "Fo
Celularity Releases CEO Letter to Shareholders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Celularity Releases CEO Letter to Shareholders January 18, 2024 | 8 min read Twitter LinkedIn Facebook Email Print Celularity Inc. (Nasdaq: CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder. FLORHAM PARK, N.J., Jan. 18, 2024 (GLOBE NEWSWI … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit March 14, 2024 | 5 min read Twitter LinkedIn Facebook Email Print Celularity Inc. announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present on the promise of cellular t … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Superstar Investors Jump in on Celgene Spinout Celularity's $250M Funding Round - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Ca … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Superstar Investors Jump in on Celgene Spinout Celularity’s $250M Funding Round February 15, 2018 | 3 min read | Mark Terry Twitter LinkedIn Facebook Email Print Celularity is a biotech founded by stem cell pioneer Robert Hariri, MD, PhD. With a high-profile group of investors and backers, Cel … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Robert Hariri: Developing Cost-Effective Cell Therapies From Placentas - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Robert Hariri: Developing Cost-Effective Cell Therapies From Placentas April 24, 2024 | 5 min read | Neil Versel Twitter LinkedIn Facebook Email Print Robert Hariri/Celularity photo The Celularity CEO and founder tells BioSpace he believes that placenta-derived cells are the futu … Mission Hariri, once a practicing physician, left the hospital world after his fellowship and has been following an entrepreneurial path ever since. His mission is to create what he calls “living-cell medicine”—and to make it cost-effective. “For 30 years, I have focused on the fact that for cell therapy to have a meaningful role in medicine, it has to do more than just transform the way the patients are treated and their outcomes,” Hariri said. “It has to fit in an already … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Robert Hariri – Longevity Med Summit Skip to content 21-22 April, 2027 Business Design Centre, London HOME ABOUT ABOUT THE SUMMIT VENUE AGENDA MEET 2026 SPEAKERS SUMMIT PROGRAMME 2026 2025 LMS CONFERENCES REPORT EXHIBITION TARGET AUDIENCE BECOME AN EXHIBITOR SPONSOR OPPORTUNITIES TAKE PART ABSTRACT SUBMISSIONS PRESS PRESS REGISTRATION LONGEVITY MED BLOG VENUE TICKETS CONTACT US HOME ABOUT ABOUT THE SUMMIT VENUE AGENDA MEET 2026 SPEAKERS SUMMIT PROGRAMME 2026 2025 LMS CONFERENCES REPORT EXHIBITION TARGET AUDIENCE BECOME AN EXHIBITOR SPONSOR OPPORTUNITIES TAKE PART ABSTRACT SUBMISSIONS PRE
17th Annual World Congress of Society for Brain Mapping & Therapeutics, "Spine and Mental Disorders." Latest state of science, advances and innovation. #CME Accredited by The Johns Hopkins University School of Medicine and the Saint Louis University Saint Louis University The Johns Hopkins University School of Medicine The accreditation apply to nursing staff as well #SBMT2020 500+ Speakers, Workshops, Keynotes, Cadaver labs by Celularity Inc., Poster presentations and Exhibitor-Attendee dedicated time. Poster Submission deadline has been extended until March 5th, 2020. https://w
Pipeline – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers MENU Allogeneic Placental-Derived Product Candidates Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic products for indications where the demonstrated properties of such cells could
Register to Exhibit at the Largest & Original Forum for Prec. Med Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdo … ogin / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry media / influencer pass CONTACT US ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ GET UPDATES Past Event PMWC, Feb 5-7, 2025 Attend Program Schedule Honorees Speakers Showcases Exhibits + Map Travel Venue Sightseeing Reduced Rates Hotel Flights Login / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to sp … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
Tour Our Facility – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers MENU A fully integrated, purpose-built research, clinical, and manufacturing center. Clinical Scale Our cellular therapeutic candidates are designed and manufactured via a platform comprised of defined unit operations and technologies. The pr
[10-K] Celularity Inc Files Annual Report | CELU Annual Report (10-K) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil … ust obtain additional capital through equity, debt or strategic transactions to fund operations beyond the next 12 months and notes recent headcount and salary reductions in early 2026 to conserve cash. The company’s current revenues come primarily from biomaterials and biobanking, and it is prioritizing longevity‑focused placental cell therapies, expansion of its biomaterials pipeline and licensing or partnering older cell‑therapy assets. Positive None. Negative None. Insigh … equivalents were only $6.2 million, which management states is insufficient to fund operations for 12 months beyond the report’s issuance. The company explicitly notes “substantial doubt” about its ability to continue as a going concern and says ongoing revenues from biomaterials and biobanking do not cover operating expenses and debt service. It plans to rely on raising new equity or debt, pursuing strategic transactions, asset sales or licensing to bridge the gap. The repo … ance and market opportunities. 510(k) notification regulatory "we now intend to submit a 510(k) notification for CTW in the first half of 2025." orphan product exclusivity regulatory "the therapeutic is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications...for seven years, except in limited circumstances" See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Add … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large a
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cel
Celularity Appoints Rick Gonzalez as Chief Commercial Officer - The Globe and Mail Home Canada Business Investing Life Opinion World Politics Personal Finance Culture Sports More More Latest in More Real Estate Drive Watchlist For You Events Find clarity in the chaos. Subscribe now and save 70% Subscribe Digital access Digital + home delivery TSX 0.37 % S&P 500 -0.05 % DOW -0.09 % NASDAQ -0.24 % Oil -3.74 % Dollar 0.05 % Gold 1.2 % tsx movers: CNQ-T -0.3 % BB-T + 10.33 % SU-T -0.87 % TRP-T -0.77 % This section contains press releases and other materials from third parties (including paid c … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Subscribe Digital + Home Delivery Digital Access Globe2Go The New York Times Globe Email … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Jump to footer navigation © Copyright 2026 The Globe and Mail Inc. All rights reserved. 3
22nd Anniversary Benefit Gala - Red Door Community Skip to content Become a Member Member Login Program Resources Community Connections Expert Speaker Series Resource Directory Get Involved Donate Events / Happenings Volunteer About Us Our Mission Board of Directors Staff Financials History / Legacy Contact Us Program Resources Community Connections Expert Speaker Series Resource Directory Get Involved Donate Events / Happenings Volunteer About Us Our Mission Board of Directors Staff Financials History / Legacy Contact Us Donate 22nd Anniversary Benefit Gala [vc_row][vc_column][vc_column_ … #8221;sm” align=”center”][mk_table] HONOREES Corporate Vision Award Advances in Cancer Research Award Red Door Community Community Partner Award Celularity, Inc. Robert J. Hariri, M.D., Ph.D. Chairman, Founder & Chief Executive Officer Foundation Medicine, Inc. Troy Cox Chief Executive Officer NYC Health + Hospitals/Kings County Ernest J. Baptiste Chief Executive Officer [/mk_table][vc_column_text css=”.vc_custom_1505847597861{margin-bottom: 0px !i
Careers – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers MENU Career Opportunities At Celularity, we are on a mission to lead the next evolution in cellular medicine by fostering a diverse and inclusive workplace. Open positions We Offer: Competitive Compensation and Benefits Collaborative Work Environment S … mation. How to identify recruitment fraud Celularity applicants are required to apply via our official company website directly to our applicant tracking system ( https://celularity.com/careers/ ). Any action asking you to apply for a job that does not lead back to this site is likely to be fraudulent. Celularity only utilizes one domain for email accounts ([email protected]). Any contact by an email that does not use exactly that domain is likely to be fraudulent. Durin
Celularity Acquires CariCord, Inc., Adds Important Biosourcing Assets, Strategic Relationship with the University of Colorado’s ClinImmune Labs – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facili
EX-99.1 2 celu-ex99_1.htm EX-99.1 THE NEXT EVOLUTION IN CELLULAR MEDICINE Investor Presentation June 2023 All statements in this presentation other than statements of historical facts regarding Celularity Inc. (“Celularity”) are “forward-looking statements” reflecting management’s current beliefs and expectations, including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,
Celularity names Rick Gonzalez chief commercial officer | CELU Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks … pr 17 Late 10-K notice Negative +0.8% Nasdaq notice for late 10-K, with time to submit compliance plan. Mar 12 NEXGEL partnership Positive -0.8% Reiterated biomaterials commercialization partnership and 510(k) programs. Pattern Detected CELU’s price often diverged from the apparent tone of news, with several negative compliance headlines followed by modest gains and strategic positives sometimes met with weakness. Recent Company History Over the last few months, Celularity na
Careers – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers MENU Career Opportunities At Celularity, we are on a mission to lead the next evolution in cellular medicine by fostering a diverse and inclusive workplace. Open positions We Offer: Competitive Compensation and Benefits Collaborative Work Environment S … mation. How to identify recruitment fraud Celularity applicants are required to apply via our official company website directly to our applicant tracking system ( https://celularity.com/careers/ ). Any action asking you to apply for a job that does not lead back to this site is likely to be fraudulent. Celularity only utilizes one domain for email accounts ([email protected]). Any contact by an email that does not use exactly that domain is likely to be fraudulent. Durin
425 1 ea143859-425_gxacquisition.htm FORM 425 Filed by GX Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: GX Acquisition Corp. Commission File No.: 001-38914 The following communication was made available by Celularity Inc. on July 7, 2021. Celularity Founder, Chairman and Chief Executive Officer, Robert J. Hariri, M.D., Ph.D., Dually Awarded for Pioneering Contributions in Medicine and Leadership The Brain Mapping Foundation and the Society fo … Hariri, the 18 th Past President of SBMT, will receive the Pioneer in Medicine Award for his innovative work in cellular therapy and the Golden Axon Award for his contributions and presidential leadership of SBMT during the COVID-19 pandemic securing food and personal protective equipment (PPE) for frontline workers and supporting policy initiatives in public health. In addition, Dr. Hariri led the first clinical trial employing a cellular therapy for COVID-19. Under Dr. Har … ology, predictive modeling, device, imaging, AI and predictive modeling and the application of augmented and virtual reality (AR and VR). Celularity will be the integrator and herald of cellular therapeutics because of Dr. Hariri.” The Pioneer in Medicine Award is presented to individuals who have significantly contributed to scientific advancements in the fields of medicine and image guided therapy through a multidisciplinary approach. Their groundbreaking … f-the-art technology and scientific discovery a reality. The Golden Axon Award is presented to individuals outside of the medical community who inspire with goodwill and an enthusiastic interest in science, technology and medicine. Named for the neuron cell fiber that carries outgoing messages to other target cells, the founding principle of the Axon Award is to recognize a highly regarded individual in the public sector who helps raise awareness and funding of S
Celularity and Gaithersburg's MaxCyte Sign Strategic Platform License to Advance Celularity’s Off-the-shelf Allogeneic Cellular Therapy Product Candidates | BioBuzz All Regions All Regions BioHealth Capital Region Greater Philadelphia Research Triangle Park News Events BioCatalyst Program Sign Up BioHealth Capital Region People Celularity and Gaithersburg’s MaxCyte Sign Strategic Platform License to Advance Celularity’s Off-the-shelf Allogeneic Cellular Therapy Product Candidates By BioBuzz Networks · Published December 2, 2024 · 4 min read · BioHealth Capital Region &larr … ite Pharma Maryland Maryland Department of Commerce Maryland Stem Cell Research Fund Maryland Tech Council Maxcyte Maxim Biomedical MaximBio Mcbee Moore and Vanik medicinegaithersburgmarylandmaxcyte Medimmune Merck NeoImmuneTech NexImmune Novavax People On The Move PQE Group Press Release Qiagen REGENXBIO regioncell Sirnaomics Technology TEDCO therapiesbiohealth therapiescellular Tonix Pharmaceuticals United States Pharmacopeia United Therapeutics University of Maryland Balti
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedi … cal cancers and solid tumors as well as infectious disease. Celularity plans to submit its initial CYNK-101 investigational new drug ("IND") application in the first half of 2021 to investigate CYNK-101 in combination with a monoclonal antibody ("mAb") to target HER2+ cancers, such as gastric cancer. The Phase 1/2a clinical trial will commence in 2021. CyCART-19 is a placental-derived T cell therapy engineered with a chimeric antigen receptor ("CAR") that is cryopreserv … iferative potential in vivo. Celularity plans to file its initial CyCART-19 IND application and to commence a Phase 1/2a clinical trial in the first half of 2021. CYNK-001 is a non-genetically modified NK cell therapy product being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers, solid tumors, and infectious disease. CYNK-001 is in development for the treatment of acute myeloid leukemia ("AML"), a blood c … atment of degenerative diseases, including Crohn's disease. Celularity plans to submit an IND in the second half of 2021 and to commence a Phase 1/2a study of APPL-001 for the treatment of Crohn's disease in 2022. Celularity also plans to use the funding from the transaction to bolster the continued build-out of internal discovery capabilities, enhance business development activities and support general corporate activities. Celularity's current science is the product of over … Celularity currently has four active and enrolling clinical trials and plans to submit three additional investigational new drug ("IND") applications in 2021. The Celularity IMPACT platform capitalizes on the benefits of placental-derived cells to target multiple diseases, and provides seamless integration, from bio-sourcing through manufacturing
%PDF-1.3 %��������� 3 0 obj > stream x�V�n�0}�WL��Y`]�/� @B�j$ (hժ�,���sllj�ݮ ��xl� �93ޟtN?I���T��h(�Ƚ#k�^��F�gw�6w$���[��Yʆ:X:v�tC�9�~� n] �� $F��ɒ ����Y|)+b� n��K��ܥs&��4 a����6L���)��c�zWh9�����,q���!]���K�҉s� Y4����(R�E��ب��5�ӝ@mu��xC@t3�g>���(����Y>�,#�=?t���0�r:�(�PG�6�eF��h=�}�� |�XwPF����O|�� �m� )�Y+�y�.]j��9����W>@S���$R������� endstream endobj 1 0 obj > endobj 4 0 obj > /Font > /XObject > >> endobj 9 0 obj > stream x�{o���B�Fj��6j E�VH���`LRjp¥��AҀ��r|l�ˁ� �`�@��$���4I�����C� �L�2;;���������;���>Y{/���?
Celularity Inc. – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers MENU Celularity Inc. Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unpara
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc. – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded
%PDF-1.7 %���� 1 0 obj >/Metadata 9485 0 R/ViewerPreferences 9486 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x���[k�@F���(�a=3{� B ��Tŗ^6m!�!1�Ƀ����Y[�U��$���9G3_�z�}^>η0� �W�!�BDb�*�` �f�g�/�g��o�ZX��3���0:Bm;��y�9Ϡ�������ɰ^]�`�'����h[��D f��'V���Z����j�`�) �@�f���C5�f�LFy0 ��9ؿ����rG�VJ:�c�/ ��� ��>R�W�[����S�b�Hlˑ���s�ȫN�̉%�2��"�FX�TD2�ӬH��BX�a��n�s�g�E���E ��G�=@��guH�ƾU�wR.�ĥݣV+S���z��lz�ƽoD]_:�}�fV�T���9����p
Celularity Announces Closing of Transaction with NexGel – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Ex
%PDF-1.6 %���� 4101 0 obj > endobj 4119 0 obj >/Filter/FlateDecode/ID[ ]/Index[4101 33]/Info 4100 0 R/Length 101/Prev 3866915/Root 4102 0 R/Size 4134/Type/XRef/W[1 3 1]>>stream h�bbd```b``� "_�H��`�� ��3XD LN� �w{>#���zF*��>��`j�K endstream endobj startxref 0 %%EOF 4133 0 obj >stream h�b```f``z�����q�A�DX��, & vIG$�H `f�Tb"1�� @�E��C4�����_� �g��zХC����o�2p&�g�U����0�)�!߁� CL�畊77��g�f���$�t+wPԴ� ���+�8,����%(�x�ŋ�%I�5� �����x%BJP���!�=�( Q%����x+GJPpb�d� VA�X�v���� ��w�\\B�9T1����^aK(_�����4����Q�Ȯ�".)�!i�Q �Bb�r���$���%r�G2/r�������GP�u�1�c�M@C$]g8]�9S … :0090245c-1681-482e-a759-1e9557d2cdf0 uuid:966d989f-6f43-4dbb-97ab-2ff45a87f2af application/pdf Program team rosters – Updated on 29-NOV-2022 Jonathan Tayco Adobe PDF Library 24.5.175 0x010100DD83DB9D3BFAD74883D4F3D6798BE68D endstream endobj 419 0 obj >stream hޜ���@Ee��y�3!4�6�� ��Q#Z����`i�f�Y��=���C��3y7�,e'�p9���C]W����N��| ����i�B\BZB�áڽnC���al���P�q�RY�����>L���W�`�F�%�̬ >stream h�l��J�@Eeޚ >/Filter/FlateDecode/ID[ ]/Info 4100 0 R/Length 1344/Root 4102 0 R
Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T
%PDF-1.6 %���� 422 0 obj > endobj 430 0 obj >/Filter/FlateDecode/ID[ ]/Index[422 14]/Info 421 0 R/Length 58/Prev 252017/Root 423 0 R/Size 436/Type/XRef/W[1 2 1]>>stream h�bbd``b`����G�Hp������#�8�����h R���D�g�� `�k� endstream endobj startxref 0 %%EOF 435 0 obj >stream h�b```�� � |� � ����� � = �>�� BI�43l����'PE_����ʌ�3 �fMkw � >/Metadata 39 0 R/OCProperties >/OCGs[431 0 R]>>/Outlines 59 0 R/PageLayout/SinglePage/Pages 420 0 R/StructTreeRoot 76 0 R/Type/Catalog>> endobj 424 0 obj >/Properties >/Shading >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 425 0 obj >stream … :0ffe023b-5ab9-4eaf-a6a5-c3b829c6e83a uuid:139dadd4-f550-42b0-a6d5-d469d046af1c application/pdf PowerPoint Presentation Ankur Garg Adobe PDF Library 21.5.80 0x010100AD126CDB39F91440A79EDDDF56E0A6D2 endstream endobj 40 0 obj >stream h�212P0P���w�/�+Q����L)�612�)�I30i �C(Se�b�C* R��S��� ��� endstream endobj 41 0 obj >stream h�l��N�0 �W�m��I�nEӤ0��I9���@5#� ��d��j�ok���TnN/,���Y�}���qL���Fc���Cm� ��]�ik���="�M�ע�wB!M 1$*�րѰ�V75���`�uM >/Filter/FlateDec
%PDF-1.7 %���� 1 0 obj >/Metadata 2173 0 R/ViewerPreferences 2174 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x���[O�0��#�;�G��� !�XP[d ��B�BE+���9N��-��5qj���w.>�������� ����3�q΅��A� �氜�ٷ#X�Y�����)���O�Vpevf� ��� �id��ȿ5�q���C� y��'`�f҃Q���Zh3����bKL�&f1�mL �1n~�d��Vk�{C�6��>%�%5n���XÅ.V� [�־��� ����-8����Ű ��� ���-Q��Y�Rx��'T��Ғ?T����L\�tǃ�rI;"������Tr��\��� �� �i���7�(��� u�C8���)�s_8_��R%x�e��� endstream end
%PDF-1.7 %���� 1 0 obj >/Metadata 1710 0 R/ViewerPreferences 1711 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��U�j�@}� �Qx�� �@s%���V�C��(N�VR� ��;+���ih ffwv.�̬֓��ᮚ����~�J(��sj�i JRh� > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj >>> endobj 12 0 obj > stream x�������� �ۃCA�_;��)�� endstream endobj 13 0 obj > stream x��ֱjZ@�D����� ��`�����4i ]^r�N�|�����w
Celularity | Florham Park other | Altss For Asset Classes Solutions Compare Case Studies Blog Book a demo Home Profiles Celularity other Updated: Jun 3, 2026 Celularity Founded in 2017 by Robert Hariri, Celularity emerged from Hariri's earlier work at Celgene Cellular Therapeutics and Anthrogenesis, where he pioneered the... Celularity Founded in 2017 by Robert Hariri, Celularity emerged from Hariri's earlier work at Celgene Cellular Therapeutics and Anthrogenesis, where he pioneered the harvesting of stem and progenitor cells from human placental tissue. Hariri, also co-founder of H … Preqin Altss vs PitchBook Altss vs FINTRX Altss vs Dakota Company About us Why Submit Data How we Collect Data Press Careers Contribute Submit your firm Submit a deal Submit a fund
%PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x����j�@F�y�o����ąъKK]Hb� D�VK �36hԈ�����{ν��V�1�]�v�n���00��B�&"à�* �s ��4�O���p�v���L���z@ ��0J$^"Qe ��Y�9" Q���šcm/|Y�q2wV��x�t����ꪴ�����Fr��S��5p>��Qaw3����8@��jU�Z�]a �2��)�c��:(��s > endobj 6 0 obj > stream ����JFIF����C $.' ",# (7),01444 '9=82 �R�R�h��K�h���� E ʊ`--6���(���������RR���(��(��(��(��(��(��(��(��(��( … ��� ��0�V��e��*�,���"��'Kr 1�# ��I�[a��:3��o� �;�#?�'إu��'�9o��{�? �(�e�rfP�.G�b����[75�\F-�^�m�� "k�߲Cf�pX���GZ��7U"��8#�Q2! w�>��سĕ�k|�g/iQ�t;�F���W�d`դ��|�X�a Ê�+����5{�fܦ���d-��9� �{���*�Q^K� 6��*�v2�����.Eԇb5��q�Y&=���5��{:�g"�ǧ������VO�����dꥳ!���v �ο�:_�G���.� P k}���x�i0+ �T��u��E��$3+�3�v���ϣ���-�~���'�^��=4`���;�W�Vsx�|�[|(Da���f� �=)�����_��5��nv���L���~� v��j��"�"#��wdg��b�|g%����{���w ��H=9�����B�TF�h �&`�BI �k��M�['� 1����
Careers – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers MENU Career Opportunities At Celularity, we are on a mission to lead the next evolution in cellular medicine by fostering a diverse and inclusive workplace. Open positions We Offer: Competitive Compensation and Benefits Collaborative Work Environment S … mation. How to identify recruitment fraud Celularity applicants are required to apply via our official company website directly to our applicant tracking system ( https://celularity.com/careers/ ). Any action asking you to apply for a job that does not lead back to this site is likely to be fraudulent. Celularity only utilizes one domain for email accounts ([email protected]). Any contact by an email that does not use exactly that domain is likely to be fraudulent. Durin
Celularity | S32 Job Board Search jobs Explore companies Join talent network Talent My job alerts Celularity celularity.com Locations Madison, WI, USA · Carlton VIC 3053, Australia · Florham Park, NJ, USA · Warren, OH, USA industry Biotechnology · Health Care · Healthcare · Therapeutics · Wellness Size 51 - 200 employees Stage Other founded in 2017 Socials LinkedIn Crunchbase Twitter Facebook Instagram About Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmo
Celularity - Director, Quality and Regulatory In order to use this site, it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser . All Jobs > Director, Quality and Regulatory Celularity Apply Director, Quality and Regulatory Morristown, NJ • Quality Apply Job Type Full-time Description About Celularity Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity … schedule. ***THIS ROLE DOES NOT PROVIDE RELOCATION ***NO AGENCIES PLEASE Apply View All Jobs Powered by Payroll & HR Software
%PDF-1.6 %���� 5307 0 obj > endobj 5327 0 obj >/Filter/FlateDecode/ID[ ]/Index[5307 38]/Info 5306 0 R/Length 109/Prev 12920639/Root 5308 0 R/Size 5345/Type/XRef/W[1 3 1]>>stream h�bbd```b``���/��f�: D�,�L�`r&�d���� r�3��� �� H2V��ؙ) �+D����k@$��d�� $� �c`bd��e`� ����G���] endstream endobj startxref 0 %%EOF 5344 0 obj >stream h��T�oe ��ve �[7�R�um5� s,�@��B[��16B��0e� 2�6�SW�m �V�92R�g0)"��� ���Dy�IJ_"F�?h��2�|r����}{���(����U*P�4Nв�{�@jƔƮet8ll���ط *� ����� 1�z q�JUR{D1k���u �xh��7Ȼ���V̦�s��� [u������6�dl�������>ω�vw��/mi �?��9���1��i�L��� �j�#1Â�ѵDF�l��V] �y� … ��EF��q�rf� CįQ9ZY�$r!���6m �)�4� ��V�9�k�J�$#�� Fь�X��٥�C��p�[��ģ)C���S�;rFP#�I�m�K�G ɺ��z���j>>��X�9,�ZL-j��Ib�k��ȉ8�˚?v�t���� �x������P�IO}�_ay@ ��:����|Ve�6�����ubd/e�3 T� Sؓ�7X����?MM�!���Լu�O��t����P Cbt;���i����ް��a��@gW��#�@��4c�9.D���o� z2>M�5��i�~�u0� �q�s �wQ�9�ǸLt��삟�Mz)>���kɝ���I�;���io�"���U)��]$Y���L >� $����$T����:gUo$���UK���,�C�`sCMAJMÄ��K��C(��g]���ٮ9�s�U�G�0?����L�5��� �QM%��0O�l��5&���`�Ƒ 1,��x�'���{��k+�mY�}��� … :11c42115-0672-4aa0-aba7-d7128d98cc56 uuid:c8a96030-bca5-4b13-95b0-ec5d8b3c69aa application/pdf Program team rosters – Updated on 29-NOV-2022 Jonathan Tayco Adobe PDF Library 24.2.23 0x010100DD83DB9D3BFAD74883D4F3D6798BE68D endstream endobj 707 0 obj >stream hޜ��n�0 E�`�=� K�.AЭ��Aѥ-����u� A��b^1�yEۥ 1�4%�K4J��$�g2I뢐��W%˶�ye�O�)C$*j���g���Q�=㔸m6�����7y��_�� {L{�g�4=�~ ������ݞ�������C�!����� �����Y�@�?q ���8��S`C�����WP\`��l� ��(&G��s�o�R�ñp.UD�5l��v�`�
CELU Stock Price and Chart — NASDAQ:CELU — TradingView Search Products Community Markets Brokers More EN Get started Markets / USA / Stocks / Commercial Services / Miscellaneous Commercial Services / CELU Celularity Inc. CELU Nasdaq Stock Market CELU Nasdaq Stock Market CELU Nasdaq Stock Market CELU Nasdaq Stock Market Market closed No trades No trades Overview Financials News Documents Community Technicals Forecasts Seasonals Options More Full chart Full chart Full chart Full chart 1 day −6.81% 5 days −19.75% 1 month −31.97% 6 months −53.03% Year to date −44.14% 1 year −66.12% 5 years −99.39%
Raven.config('https://[email protected]/147999').install(); Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation | INN Connect with us Information About Us Contact Us Careers Partnerships Advertise With Us Authors Browse Topics Events Disclaimer Privacy Policy WORLD EDITION Australia North America World Login Investing News Network Your trusted source for investing success WORLD EDITION North America Australia World My INN Videos Companies Press Releases Private Placements SUBSCRIBE Reports & Guides M … ng 14h MAYFAIR ANNOUNCES RESULTS OF 2026 ANNUAL GENERAL AND SPECIAL MEETING AND GRANT OF STOCK OPTIONS 15h Related News agriculture investing Update Strengthens Cu-Au Targets, Glava & Torsby West 10h oil and gas investing Top 5 Australian Mining Stocks This Week: Lakes Blue Energy Rises as Wombat Gas Field Progresses 12h gold investing Rhona O'Connell: Gold Price Drop — Why it Happened, What's Next 12h precious metals investing New Found Gold Announces Results of … esting MAYFAIR ANNOUNCES RESULTS OF 2026 ANNUAL GENERAL AND SPECIAL MEETING AND GRANT OF STOCK OPTIONS 15h base metals investing Steadright Cancels Purchase of 80% Interest in Moroccan Antimony Company 22h base metals investing Exploration Momentum Continues with Launch of District-Scale Prospecting Program 23h TOP STOCKS American Battery 4.03 0.24 Aion Therapeutic 0.10 -0.01 Cybin Corp 2.14 0.00
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Celularity – The Next Evolution in Cellular Medicine Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers MENU TURNING NATURE’S MIRACLE INTO MEDICAL BREAKTHROUGHS Celularity Inc. (NASDAQ: CELU) is an innovative regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and
Leadership – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers MENU Executive Leadership We have a deep, seasoned leadership team with experience in all aspects of cellular and regenerative medicine. Robert J. Hariri, M.D., Ph.D. Chairperson, Founder, and CEO Functional Area Leadership Anna Gosiewska, Ph.D. R&a
Robert J. Hariri – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers MENU Robert J. Hariri, M.D., Ph.D. Dr. Bob Hariri is an accomplished surgeon, biomedical scientist, and serial entrepreneur in two technology sectors, biomedicine and aerospace. He is the chairperson, founder, and chief executive officer of Ce … apy and regenerative medicine. Dr. Hariri twice received the Thomas Alva Edison Award for invention, in 2007 and 2011, and is a recipient of the Children’s Brain Tumor Foundation’s Fred J. Epstein Lifetime Achievement Award. Dr. Hariri was recipient of the Genius of New Jersey Award in 2019 and over the years has received numerous other honors for his many contributions to the fields of biomedicine and aviation. Dr. Hariri is an Adjunct Professor of Neurosurgery and member of … logy Council of the College of Physicians and Surgeons. He is a member of the X PRIZE Foundation scientific advisory board for the Archon X PRIZE for Genomics. Dr. Hariri is a trustee and vice-chair of the Liberty Science Center. In 2010 he was appointed a Commissioner of Cancer Research by New Jersey Governor Chris Christie. Dr. Hariri completed his undergraduate training at Columbia University School of Engineering and Applied Sciences and Columbia College. He received his … om Cornell University, where he was the recipient of both the Julian R. Rachele Award and the Doctoral Dissertation Award. He was a surgical resident and fellow in neurosurgery at The New York Hospital-Cornell Medical Center and served as an Assistant Professor of Neurosurgery and Associate Research Professor of Surgery at Cornell and Co-director of the Aitken Laboratory in Neurosurgery. When he is not in the laboratory or the corporate boardroom, Dr. Hariri is a jet-rated co
Peter Diamandis 01 de-extinction 02 species index 03 conservation 04 science & technology 05 a better world 06 company 07 labs 08 news Index + --> Page: peter-diamandis --> page section - --> Page Section: Page Navigation PAGE SELECTION --> 000-00 home 001-00 de-extinction 002-00 species 002A-00 woolly mammoth 002B-00 thylacine 002C-00 dodo 002E-00 dire wolf 002F-00 moa 002G-00 bluebuck 003-00 conservation 004-00 science & technology 005-00 A BETTER WORLD 006-00 COMPANY 007-00 Labs 008-00 NEWS 009-00 Advisors 010-00 education 011-00 elephant conservation Page Sections for: peter-diamandis 02a … ure capital and education. He is co-founder of BOLD Capital Partners, a venture fund with $300 investing in exponential technologies and longevity. He is co-founder and Vice Chairman of Celularity, Inc., and Vaxxinity, Inc. Diamandis is a New York Times Bestselling author of two books: Abundance – The Future Is Better Than You Think and BOLD – How to go Big, Create Wealth & Impact the World. His newest book in this series of exponential technologies—The Future is Faster T
Peter Diamandis — Elevian About Us Science Media Careers Investors Contact About Us Science Media Careers Investors Contact Reimagine Aging Peter Diamandis, MD — Elevian Co-Founder; xPrize, Singularity U, Celularity, Human Longevity Inc. Dr. Diamandis is a pioneer in the fields of innovation, commercial space and longevity. In 2014 he was named one of "The World’s 50 Greatest Leaders" – by Fortune Magazine. Diamandis is Founder and Executive Chairman of the XPRIZE Foundation. Diamandis is also the Co-Founder and Vice-Chairman of Human Longevity, Inc. (HLI) and Celularity, genomics diagno
Board of Directors – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers MENU Board of Directors Robert J. Hariri, M.D., Ph.D Chairperson, Founder & CEO Peter Diamandis, M.D. Director Geoffrey Shiu Fei Ling, M.D., Ph.D. Director Diane Parks Director Vincent LeVien Director Celularity is a biotechnology compan
Raj Joshi - Conference Contractpharma Skip to content EXHIBIT SPACE INQUIRIES 2026 REGISTER NOW September 24-25, 2026 | Hyatt Regency, New Brunswick, NJ Exhibitor Info Exhibitor Info Exhibitors Attendee Inquiries Exhibitor Inquiries Sponsors Description Sponsor Packages Sponsor Tools Agenda Submission Request Speakers Hotel Photos Testimonials Contact ContractPharma.com Menu Exhibitor Info Exhibitor Info Exhibitors Attendee Inquiries Exhibitor Inquiries Sponsors Description Sponsor Packages Sponsor Tools Agenda Submission Request Speakers Hotel Photos Testimonials Contact ContractPharma.com Ba
%PDF-1.7 %���� 31385 0 obj > endobj 31395 0 obj ]>>stream x��� �P�{y��|�P�1���h���^(�%��d2V%'� F����� ��|�q��A֪h� �1NH�"�9.��@�*�h��= ;}9! endstream endobj 31387 0 obj >stream x�c```b``(``f``�� Ȁ� , �@̱��`�`T���P.�|�9r�S���� �}"O8v�,q��Κ�� еn��&Gyˉ�Ê2�x�Q����Yò�i�A-���6r���r�r5;Z3L����f��pe�mJPa�;a���$ ����p�`� � �"�\��{5%>�09����4��q��'}~����� �O\9,�.W����x�C� ��$�/�l̈ �6�Jb��z�)����� !/��D�#9/4P���a��h��X�aJ�{�L��UN��'׃"�^�m�5�̭ˤ��#ߌ�.S�qڷ\>���/�n���E2���tX ^����� M6� >>> endobj 31388 0 obj >/MediaBox[0 0 595.27 841.9099]/Parent 31333 0 R/Res … ��1(m�Ǹ]S\9~����!���#@p�S�2#���ߑ���j���Ɣ3�������;�[S�E�4� ��]@� �U:��rfp���������5[�-u��kq �����caO�Kɠ�!��*��n��$�6KYo�e��\�=э̌b2(m.���+g���� �=�W�@� S�2���2� �(m���yc����0��� �A�=�- P�PL�K�`Mbm�����ʙ����fiݢq�œX�dr'��X���Fp�hC�Y�-g��|�Y�z�,b ��O�*�Yu����f�&��D� \���Dh���LT��Z�����C *~{o�+猃#zx�IĨN�.����.b(��Z3!��(0�. �A�R5F�ԝp��3����҆I����@�S�21"����1�\�L�rfp��js�a��l��B �߅���� G�N ��ai, g�XKL�&�P��'�D18���JG��\Jp6��%���(����|U … PScript5.dll Version 5.2.2 2025-11-07T12:09:15-05:00 2025-11-07T12:09:15-05:00 application/pdf Submission Proof - Z:\2025 OPERATIONS\EDGAR\11 NOVEMBER\Celularity, Inc\11-06-2025\Form ARS\Draft\Production\Celularity, Inc 11 AdamAFlury Acrobat Distiller 25.0 (Windows) uuid:7525d2a6-2e88-4dbb-8947-c73d07bb8b31 uuid:9e7341a0-6eaf-4ff6-9559-a24b1fe6c23f endstream endobj 781 0 obj >stream xڝ�Ao7F� oI�8�� A�^�A�[у �m�4. ���Y�Gځ�:��Zj�|3� �%�(% 1$;r ��J�����2�Vb緖�L��Jȭ�V ZZo�
Celularity Inc.: Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on “The Science and Technology for E... | 6ix News Home News Celularity Inc. Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on “The Science and Technology for Extending H... Business Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on “The Science and Technology for Extending Healthy Human Lifespan” Company is investigating advanced therapies for the treatment of cancer, degenerative diseases, and immune and infectious diseases Participation in FII article Celul … gional companies, including Tamer Group, Sanabil Investments, Public Investment Fund (PIF), and NEOM, and look forward to building these relationships and exploring opportunities to be part of the Saudi Vision 2030 plan for healthcare innovation and development.” Established in 2017 by the PIF, Saudi Arabia's main sovereign wealth fund,... View stock analysis, news, and events for Celularity Inc.
Celularity Inc (Form: 8-K, Received: 02/24/2025 09:00:22) false 0001752828 0001752828 2025-02-24 2025-02-24 0001752828 CELU:ClassCommonStock0.0001ParValuePerShareMember 2025-02-24 2025-02-24 0001752828 CELU:WarrantsEachExercisableForOnetenthOfOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2025-02-24 2025-02-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date o
Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™” - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA M … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™” April 12, 2023 | 5 min read Twitter LinkedIn Facebook Email Print Celularity Inc. announced that Robert Hariri, M.D., Ph.D., Celularity’s Chief E … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Demos: UI Controls and Frameworks --> Demos: UI Controls and Frameworks | DevExpress Chat Now Cart My Downloads Free Trial Log In Products Products MULTI-PLATFORM PACKAGES Universal Subscription Our Best Value – includes over 600 UI Controls, our award-winning reporting platform, DevExpress Dashboard, the eXpressApp Framework, CodeRush for Visual Studio and more. DXperience Subscription Save Hundreds – includes DevExpress UI Controls for WinForms, Blazor, ASP.NET Core (MVC & Razor Pages), ASP.NET Web Forms, MVC 5, WPF, our award-winning reporting platform and CodeRush for Visual Studio. HIGHLI … cumentation Code Examples Demos Training Need help or require more information? Submit your support inquiries via the DevExpress Support Center for assistance. Blogs About Us About Us CONNECT WITH DEVEXPRESS Blogs Events, Meetups and Tradeshows LEARN MORE ABOUT DEVEXPRESS About Us Careers / Job Opportunities News User Comments and Case Studies Our Awards MVP Program Announcing DevExpress Universal v26.1 Developer Express Inc is proud to announce the immediate availability of … ad Download DevExpress WinForms demo applications from GitHub. Outlook-Inspired Application Build apps with the UI elements your customers have come to expect from the world's most popular software suite. Run Demo Dental Clinic Application Create a relatively modern UX – a user experience that can be applied to different industries with minimal changes. Run Demo Stock Market Trader Build WinForms applications that replicate the innovative navigation UI. Run Demo New HTML & … S markup. Run Demo Learn more about HTML & CSS Support Touch-Enabled Hybrid Application Build touch-friendly WinForms applications that meet the evolving needs of your enterprise. Run Demo Fluent Mail Client Application In this demo application we use our Fluent Design Form to replicate Microsoft Mail's UI. Run Demo Help Resources Documentation Online Training Examples Tutorial Videos Getting Started with the Grid Control Getting Started with the Ribbon Control Getting St … UI — Case Study by DataWerkes: Field Services Management Platform (TimeWerkes) Application Security — Documents Are Untrusted Input Application Security — Stronger Hashes and Safer Passwords WPF Demos With over 130 optimized UI controls and libraries, the DevExpress WPF Subscription , can help you create powerful and visually stunning business s
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers – Celularity Home About About Us Leadership Board of Directors Scientific Advisors Manufacturing Biobanking Tour Our Facility Expanded Access Policy Science Power of Placenta NK Cell Platform T Cell Platform MLASCs Exosomes Advanced Biomaterials Pipeline Newsroom Investors Investor Relations SEC Filings Corporate Governance Careers Home About About Us Leadership Board of Directors
%PDF-1.4 1 0 obj > endobj 3 0 obj > endobj 4 0 obj [/Pattern /DeviceRGB] endobj 6 0 obj > stream ����JFIFHH��C ��C ��d�"�� ���}!1AQa"q2���#B��R��$3br� %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������� ���w!1AQaq"2�B���� #3R�br� $4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz�������������������������������������������������������������������������� … �7��-�a�� [���^��c�a��� �6�?X�;Y� ���¶�j���`FoCPn��w�u��DNJ�Qk��1u�I�`��ìRfp�7��Į�Zv �y�� B� ����{3}��d��rCk[����-D�7����q� /Y��m,- f�p= �� ��Tw��ʌ���p� ��C�$�)*��o2�~�q���.�5nH���t�� _3A(&r�ݝX�ڊ{MD9$�Fk� a�'B�+B�M��6[5�_o���l��%aq��Kd��DE2�����j^0ą�0�5�@���A鄚�-��ýN���o�ʮݼ��� �� 0�$����'ss�K�9&i��Cj�!��� ���!>\)�p���ݛm��l\�];�:[��Hэ��5��(���� %�wJ,�5��+r�)�b3���/�(�˸|�q�� �E��WBh�L ��yJ���/Id���~ !�.�!�e�N���놺�r���n*�K����o������F�bQ
false 0001752828 0001752828 2025-08-05 2025-08-05 0001752828 CELU:ClassCommonStock0.0001ParValuePerShareMember 2025-08-05 2025-08-05 0001752828 CELU:WarrantsEachExercisableForOnetenthOfOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2025-08-05 2025-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): August 5, 2025